نتایج جستجو برای: cell utilization

تعداد نتایج: 1795513  

Journal: :Journal of animal science 1973
P D Platter E R Peo P E Vipperman P J Cunningham

Journal: :QJM : monthly journal of the Association of Physicians 2006
D Raveh E Muallem-Zilcha A Greenberg Y Wiener-Well Y Schlesinger A M Yinnon

BACKGROUND Cefepime, piperacillin-tazobactam and meropenem are among the broadest-spectrum and most expensive antimicrobials. AIM To evaluate guidelines for appropriate use of these drugs. METHODS We developed guidelines for use of these antibiotics, and conducted a two-phase drug utilization evaluation. We included all patients who received one of the study drugs during two 3-month periods...

2011
Sun Ah Kim Jung Hoon Kim Yoo Jin Jang Man Ho Jeon Joong Un Hwang Young Mi Jeong Kyung Suk Choi Iyn Hyang Lee Jin Ok Jeon Eun Sook Lee Eun Kyung Lee Hong Bin Kim Ho Jun Chin Ji Hye Ha Young Hoon Kim Byung Koo Lee

OBJECTIVES This report describes the development process of a drug dosing database for ethical drugs approved by the Korea Food & Drug Administration (KFDA). The goal of this study was to develop a computerized system that supports physicians' prescribing decisions, particularly in regards to medication dosing. METHODS The advisory committee, comprised of doctors, pharmacists, and nurses from...

2017
Kanishk Kala Rupinder Kaur Sodhi Upendra Kumar Jain

(150-200 words) Drug Use Evaluation (DUE) is recognized as an effective tool for detecting and improving drug use and to strengthen clinical pharmacy and patient care It is vital for almost all drugs most importantly for antibiotics for being the highly used drug in hospitals and community The objective of this study was to do drug utilization evaluation of antibiotics in dh uttarakashi. It was...

Journal: :P & T : a peer-reviewed journal for formulary management 2012
Stephen Barlas

In the Call Letter, CMS encourages ACOs to find Part D plan sponsor partners through a request for proposal process. I do believe that ACOs have an incentive to work with PDPs to control medical costs, including preventing readmissions. However, ACOs have no incentive to work to appropriately manage Part D utilization and may have incentives to increase Part D utilization to prevent the use of ...

1999
Bruce Stuart Becky A. Briesacher Frank Ahern David Kidder Christopher Zacker Gary Erwin Daniel Gilden Cheryl Fahlman

In this article the authors present population-level prevalence rates for 61 specific drug-related problems occurring in three State Medicaid programs (Maryland, Iowa, and Washington) from 1989 through 1996 and a fourth (Georgia) from 1994 through 1996. The findings represent the first application of a consistent drug utilization review (DUR) screener program to Medicaid data across States. The...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید